All stock lists
Voyager Therapeutics, Inc. (NASDAQ:VYGR)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.83+0.05 (+2.81%)
Market cap
$113M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 11, 2015
Website
Insider Score
––Not scored
VYGR Insider Score
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
VYGR analyst forecast
VYGR analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
VYGR 12-month price target
No published price targets in the last 12 months.
VYGR ratings mix, last 12 months
Buy Hold Sell
Best analysts covering VYGR
- HC Wainwright & Co.30%success rate · -25.0% avg return · 10 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
VYGR analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-17 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-11-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-09-15 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-08-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-04-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-13 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2025-03-13 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2025-03-12 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-03-12 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2025-03-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-27 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2024-11-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-10-24 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-20 |
| — | Wedbush | Neutral | — | — | Reiterated | 2024-08-07 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-07-31 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-16 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-05-15 |
| — | Wedbush | Neutral | — | — | Reiterated | 2024-05-14 |
| — | Wells Fargo | Overweight | — | — | Upgraded | 2024-01-02 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2023-08-07 |
| — | Truist Securities | Buy | — | — | Reiterated | 2023-05-10 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2023-05-10 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2023-03-10 |
| — | Chardan Capital | Neutral | — | — | Reiterated | 2021-11-03 |
| — | Baird | Outperform | — | — | Upgraded | 2021-10-07 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2021-04-19 |
| — | Baird | Neutral | — | — | Downgraded | 2021-02-26 |
| — | Wedbush | Neutral | — | — | Downgraded | 2021-02-03 |
| — | BTIG | Neutral | — | — | Downgraded | 2021-02-03 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2021-02-03 |
| — | Oppenheimer | Perform | — | — | Downgraded | 2020-11-11 |
| — | Wells Fargo | Equal Weight | — | — | Downgraded | 2020-11-10 |
| — | Raymond James | Outperform | — | — | Downgraded | 2020-11-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2020-08-04 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2020-04-15 |
| — | Nomura | Buy | — | — | Reiterated | 2020-03-30 |
| — | Benchmark | Buy | — | — | Reiterated | 2020-03-19 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2020-03-04 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2020-03-04 |
| — | Wedbush | Outperform | — | — | Reiterated | 2020-03-04 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2020-02-06 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2019-10-11 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2019-07-12 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2019-03-06 |
| — | Raymond James | Strong Buy | — | — | Upgraded | 2018-11-15 |
| — | Baird | Outperform | — | — | Reiterated | 2018-11-08 |
| — | H.C. Wainwright | Buy | — | — | Reiterated | 2018-06-04 |
| — | Wedbush | Outperform | — | — | Upgraded | 2018-05-11 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2018-03-15 |
| — | Evercore ISI Group | In Line | — | — | Downgraded | 2018-03-12 |
| — | Wedbush | Neutral | — | — | Downgraded | 2018-03-12 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2018-02-21 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2018-02-02 |
| — | BTIG Research | Buy | — | — | Reiterated | 2017-12-20 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2017-10-27 |
| — | Stifel Nicolaus | Buy | — | — | Reiterated | 2017-10-23 |
Paid research (issuer-sponsored)
These firms were paid by the company to publish research on it. Their ratings and targets are not counted in the consensus, the price target or the rankings above.
- Fundamental Research Corp · since 2021-06-30
VYGR earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2025-11-10 | -0.53 | -0.47 | $10.5M | $13.4M |
| 2026-03-09 | -0.54 | -0.46 | $10.5M | $15.3M |
| 2026-05-07 | -0.54 | -0.47 | $8.8M | $2.6M |
| 2026-08-06 | -0.48 | -0.40 | $4.5M | $3.2M |
| 2026-11-09Upcoming | -0.41 | — | $6.3M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.